Study of Pembrolizumab (MK-3475) in Platinum Pre-treated Recurrent/Metastatic Nasopharyngeal Cancer (MK-3475-122/KEYNOTE-122)

NCT02611960 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

233

Enrollment

INDUSTRY

Sponsor class

Conditions

Nasopharyngeal Neoplasms

Interventions

BIOLOGICAL: Pembrolizumab
DRUG: Capecitabine
DRUG: Gemcitabine
DRUG: Docetaxel

Sponsor

Merck Sharp & Dohme LLC